We are live on
!
Find out more
TFIPS
Towarzystwo Funduszy Inwestycyjnych PZU SA Portfolio holdings
AUM
$355M
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+0.99%
1 Year Est. Return
+44.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$68.7M
AUM Growth
-$27.9M
(-29%)
Cap. Flow
-$30.9M
Cap. Flow
% of AUM
-44.91%
Top 10 Holdings %
Top 10 Hldgs %
56.23%
Holding
371
New
22
Increased
27
Reduced
37
Closed
33
Avg Time Held
0.9
quarters
Top 10 Avg Time Held
0.2
quarters
Top 20 Avg Time Held
0.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSMC
TSM
|
+$9.91M |
| 2 |
Kinross Gold
KGC
|
+$8.08M |
| 3 |
HOLX
Hologic
HOLX
|
+$264K |
| 4 |
Pfizer
PFE
|
+$176K |
| 5 |
Insulet
PODD
|
+$174K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$9.65M |
| 2 |
Freeport-McMoran
FCX
|
+$8.47M |
| 3 |
JPMorgan Chase
JPM
|
+$5.83M |
| 4 |
NVIDIA
NVDA
|
+$5.35M |
| 5 |
Newmont
NEM
|
+$4.85M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.7% |
| 2 | Technology | 25.24% |
| 3 | Materials | 24.36% |
| 4 | Financials | 4.08% |
| 5 | Consumer Discretionary | 2.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Kinross Gold
KGC
$28.5B
| $15.5M | 22.62% |
2,330,134
+1,162,900
| +100% | +$8.08M |
2020 Q4
1 quarter
|
|
|
2
TSMC
TSM
$2.45T
| $9.46M | 13.77% |
+80,000
| New | +$9.91M |
2021 Q1
0 quarters
|
|
3
Cerence
CRNC
$366M
| $4.02M | 5.85% |
44,863
| – | – |
2020 Q4
1 quarter
|
|
4
Johnson & Johnson
JNJ
$617B
| $2.19M | 3.19% |
13,322
-20
| -0.1% | -$3.24K |
2020 Q4
1 quarter
|
|
5
UnitedHealth
UNH
$334B
| $1.79M | 2.6% |
4,805
| – | – |
2020 Q4
1 quarter
|
|
6
Abbott
ABT
$169B
| $1.25M | 1.82% |
10,444
-1,560
| -13% | -$185K |
2020 Q4
1 quarter
|
|
7
Merck
MRK
$356B
| $1.17M | 1.7% |
15,879
-4,246
| -21% | -$313K |
2020 Q4
1 quarter
|
|
8
AbbVie
ABBV
$464B
| $1.11M | 1.62% |
10,286
-1,580
| -13% | -$169K |
2020 Q4
1 quarter
|
|
9
Thermo Fisher Scientific
TMO
$242B
| $1.06M | 1.55% |
2,329
-432
| -16% | -$206K |
2020 Q4
1 quarter
|
|
10
Bristol-Myers Squibb
BMY
$125B
| $1.05M | 1.53% |
16,609
-3,050
| -16% | -$190K |
2020 Q4
1 quarter
|
|
11
Danaher
DHR
$150B
| $960K | 1.4% |
4,812
-433
| -8% | -$87.9K |
2020 Q4
1 quarter
|
|
12
Eli Lilly
LLY
$1.02T
| $857K | 1.25% |
4,587
| – | – |
2020 Q4
1 quarter
|
|
13
AstraZeneca
AZN
$243B
| $814K | 1.18% |
8,182
-3,850
| -32% | -$387K |
2020 Q4
1 quarter
|
|
|
14
Pfizer
PFE
$158B
| $780K | 1.13% |
21,526
+4,950
| +30% | +$176K |
2020 Q4
1 quarter
|
|
15
Apple
AAPL
$4.87T
| $760K | 1.11% |
6,220
-9,380
| -60% | -$1.2M |
2020 Q4
1 quarter
|
|
16
Amgen
AMGN
$218B
| $757K | 1.1% |
3,042
| – | – |
2020 Q4
1 quarter
|
|
17
Amazon
AMZN
$2.71T
| $727K | 1.06% |
4,700
-60
| -1% | -$9.51K |
2020 Q4
1 quarter
|
|
18
CVS Health
CVS
$111B
| $681K | 0.99% |
9,055
-3,667
| -29% | -$267K |
2020 Q4
1 quarter
|
|
19
Microsoft
MSFT
$3.84T
| $607K | 0.88% |
2,574
-115
| -4% | -$26.7K |
2020 Q4
1 quarter
|
|
20
Vertex Pharmaceuticals
VRTX
$128B
| $568K | 0.83% |
2,641
-700
| -21% | -$154K |
2020 Q4
1 quarter
|
|
21
Cigna
CI
$71.5B
| $562K | 0.82% |
2,326
-710
| -23% | -$158K |
2020 Q4
1 quarter
|
|
|
22
Newmont
NEM
$122B
| $555K | 0.81% |
9,201
-81,047
| -90% | -$4.85M |
2020 Q4
1 quarter
|
|
23
Boston Scientific
BSX
$61.7B
| $495K | 0.72% |
12,819
-1,443
| -10% | -$54.6K |
2020 Q4
1 quarter
|
|
|
24
NVIDIA
NVDA
$5.65T
| $489K | 0.71% |
36,600
-398,400
| -92% | -$5.35M |
2020 Q4
1 quarter
|
|
25
Elevance Health
ELV
$83.8B
| $487K | 0.71% |
1,358
+80
| +6% | +$25.7K |
2020 Q4
1 quarter
|
|
Similar funds
OCMH
FI
FPWM
SPI
WPW
OWCM
A6
ARC
Towarzystwo Funduszy Inwestycyjnych PZU SA's Q1 2021 Portfolio in Review
As of Q1 2021, Towarzystwo Funduszy Inwestycyjnych PZU SA held 371 positions worth $68.7M, down 29% from $96.6M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Towarzystwo Funduszy Inwestycyjnych PZU SA withdrew a net $30.9M in Q1 2021, closing 33 positions and reducing 37 holdings. Its most notable exit was Sanofi, an estimated $126K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 37% of assets, up from 26% a quarter earlier, followed by Technology and Materials.
Against the trend, Towarzystwo Funduszy Inwestycyjnych PZU SA opened a new position in TSMC worth $9.46M.
- Towarzystwo Funduszy Inwestycyjnych PZU SA's largest Q1 2021 buy was TSMC: 80,000 shares worth $9.46M.
- Towarzystwo Funduszy Inwestycyjnych PZU SA added most to Kinross Gold in Q1 2021, an estimated $8.08M increase.
- Towarzystwo Funduszy Inwestycyjnych PZU SA's biggest Q1 2021 reduction was Alibaba, cutting an estimated $9.65M.
- Towarzystwo Funduszy Inwestycyjnych PZU SA fully exited Sanofi in Q1 2021, selling an estimated $126K.
- Towarzystwo Funduszy Inwestycyjnych PZU SA's ten largest holdings make up 56% of its $68.7M portfolio in Q1 2021.
- Towarzystwo Funduszy Inwestycyjnych PZU SA opened 22 new positions and closed 33 in Q1 2021.
- Towarzystwo Funduszy Inwestycyjnych PZU SA's portfolio value fell 29% quarter-over-quarter to $68.7M.
Based on Towarzystwo Funduszy Inwestycyjnych PZU SA's 13F filing for Q1 2021, filed 14 Aug 2025.